Insider Transactions in Q1 2023 at Ligand Pharmaceuticals Inc (LGND)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 24
2023
|
Andrew Reardon CLO & Secretary |
SELL
Open market or private sale
|
Direct |
300
-1.81%
|
$20,700
$69.92 P/Share
|
|
Feb 23
2023
|
Todd C Davis Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,005
+19.82%
|
-
|
|
Feb 23
2023
|
Andrew Reardon CLO & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
5,668
+25.44%
|
-
|
|
Feb 23
2023
|
Matthew E Korenberg President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
9,069
+8.41%
|
-
|
|
Feb 23
2023
|
Octavio Espinoza Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,046
+20.03%
|
-
|
|
Feb 15
2023
|
Octavio Espinoza Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
849
-4.48%
|
$61,128
$72.98 P/Share
|
|
Feb 15
2023
|
Matthew E Korenberg President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,890
-3.12%
|
$208,080
$72.98 P/Share
|